Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 54

1.

Cell Surface Protein Biotinylation for SDS-PAGE Analysis.

Elia G.

Methods Mol Biol. 2019;1855:449-459. doi: 10.1007/978-1-4939-8793-1_37.

PMID:
30426438
2.

DIGE Analysis of Animal Tissues.

Di Luca A, Hamill R, Mullen AM, Elia G.

Methods Mol Biol. 2018;1664:137-152. doi: 10.1007/978-1-4939-7268-5_12.

PMID:
29019131
3.

Intralesional treatment of metastatic melanoma: a review of therapeutic options.

Weide B, Neri D, Elia G.

Cancer Immunol Immunother. 2017 May;66(5):647-656. doi: 10.1007/s00262-016-1952-0. Epub 2017 Jan 11. Review.

4.

Comparative Proteomic Profiling of Divergent Phenotypes for Water Holding Capacity across the Post Mortem Ageing Period in Porcine Muscle Exudate.

Di Luca A, Hamill RM, Mullen AM, Slavov N, Elia G.

PLoS One. 2016 Mar 7;11(3):e0150605. doi: 10.1371/journal.pone.0150605. eCollection 2016.

5.

Human plasma protein adsorption onto alumina nanoparticles relevant to orthopedic wear.

Gibbons JP, Monopoli MP, Lundqvist M, Montes-Burgos I, McGrath EE, Elia G, Lynch I, Dawson KA, Stanton KT.

J Appl Biomater Funct Mater. 2015 Jul 4;13(2):e145-55. doi: 10.5301/jabfm.5000219.

PMID:
26045225
6.

Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study.

Danielli R, Patuzzo R, Di Giacomo AM, Gallino G, Maurichi A, Di Florio A, Cutaia O, Lazzeri A, Fazio C, Miracco C, Giovannoni L, Elia G, Neri D, Maio M, Santinami M.

Cancer Immunol Immunother. 2015 Aug;64(8):999-1009. doi: 10.1007/s00262-015-1704-6. Epub 2015 May 14.

PMID:
25971540
7.

Potentiating the activity of rituximab against mantle cell lymphoma in mice by targeting interleukin-2 to the neovasculature.

Börschel N, Schwöppe C, Zerbst C, Angenendt L, Kessler T, Klapper W, Giovannoni L, Elia G, Neri D, Berdel WE, Mesters RM, Schliemann C.

Leuk Res. 2015 Jul;39(7):739-48. doi: 10.1016/j.leukres.2015.04.005. Epub 2015 Apr 17.

PMID:
25934049
8.

The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer.

Catania C, Maur M, Berardi R, Rocca A, Giacomo AM, Spitaleri G, Masini C, Pierantoni C, González-Iglesias R, Zigon G, Tasciotti A, Giovannoni L, Lovato V, Elia G, Menssen HD, Neri D, Cascinu S, Conte PF, Braud Fd.

Cell Adh Migr. 2015;9(1-2):14-21. doi: 10.4161/19336918.2014.983785.

9.

Predicting response to vascular endothelial growth factor inhibitor and chemotherapy in metastatic colorectal cancer.

Martin P, Noonan S, Mullen MP, Scaife C, Tosetto M, Nolan B, Wynne K, Hyland J, Sheahan K, Elia G, O'Donoghue D, Fennelly D, O'Sullivan J.

BMC Cancer. 2014 Nov 27;14:887. doi: 10.1186/1471-2407-14-887.

10.

Armed antibodies for cancer treatment: a promising tool in a changing era.

Danielli R, Patuzzo R, Ruffini PA, Maurichi A, Giovannoni L, Elia G, Neri D, Santinami M.

Cancer Immunol Immunother. 2015 Jan;64(1):113-21. doi: 10.1007/s00262-014-1621-0. Epub 2014 Oct 15. Review.

PMID:
25314912
11.

Blood biocompatibility of surface-bound multi-walled carbon nanotubes.

Gaffney AM, Santos-Martinez MJ, Satti A, Major TC, Wynne KJ, Gun'ko YK, Annich GM, Elia G, Radomski MW.

Nanomedicine. 2015 Jan;11(1):39-46. doi: 10.1016/j.nano.2014.07.005. Epub 2014 Jul 27.

PMID:
25072378
12.

Limited efficacy of intratumoral IL-2 applied to large melanoma metastases.

Weide B, Eigentler TK, Elia G, Neri D, Garbe C.

Cancer Immunol Immunother. 2014 Nov;63(11):1231-2. doi: 10.1007/s00262-014-1584-1. Epub 2014 Jul 24. No abstract available.

PMID:
25056818
13.

Intralesional treatment of stage III metastatic melanoma patients with L19-IL2 results in sustained clinical and systemic immunologic responses.

Weide B, Eigentler TK, Pflugfelder A, Zelba H, Martens A, Pawelec G, Giovannoni L, Ruffini PA, Elia G, Neri D, Gutzmer R, Becker JC, Garbe C.

Cancer Immunol Res. 2014 Jul;2(7):668-78. doi: 10.1158/2326-6066.CIR-13-0206. Epub 2014 Apr 4.

14.

Preclinical evaluation of IL2-based immunocytokines supports their use in combination with dacarbazine, paclitaxel and TNF-based immunotherapy.

Pretto F, Elia G, Castioni N, Neri D.

Cancer Immunol Immunother. 2014 Sep;63(9):901-10. doi: 10.1007/s00262-014-1562-7. Epub 2014 Jun 4.

PMID:
24893857
15.

Radretumab radioimmunotherapy in patients with brain metastasis: a 124I-L19SIP dosimetric PET study.

Poli GL, Bianchi C, Virotta G, Bettini A, Moretti R, Trachsel E, Elia G, Giovannoni L, Neri D, Bruno A.

Cancer Immunol Res. 2013 Aug;1(2):134-43. doi: 10.1158/2326-6066.CIR-13-0007. Epub 2013 May 20.

16.

From target discovery to clinical trials with armed antibody products.

Elia G, Fugmann T, Neri D.

J Proteomics. 2014 Jul 31;107:50-5. doi: 10.1016/j.jprot.2014.02.034. Epub 2014 Mar 12. Review.

PMID:
24631826
17.

Composition of the bovine uterine proteome is associated with stage of cycle and concentration of systemic progesterone.

Faulkner S, Elia G, O' Boyle P, Dunn M, Morris D.

Proteomics. 2013 Nov;13(22):3333-53.

PMID:
24115321
18.

Exploring the glycosylation of serum CA125.

Saldova R, Struwe WB, Wynne K, Elia G, Duffy MJ, Rudd PM.

Int J Mol Sci. 2013 Jul 26;14(8):15636-54. doi: 10.3390/ijms140815636.

19.

The presence of outer arm fucose residues on the N-glycans of tissue inhibitor of metalloproteinases-1 reduces its activity.

Kim HIe, Saldova R, Park JH, Lee YH, Harvey DJ, Wormald MR, Wynne K, Elia G, Kim HJ, Rudd PM, Lee ST.

J Proteome Res. 2013 Aug 2;12(8):3547-60. doi: 10.1021/pr400276r. Epub 2013 Jul 1.

PMID:
23815085
20.

Monitoring post mortem changes in porcine muscle through 2-D DIGE proteome analysis of Longissimus muscle exudate.

Di Luca A, Elia G, Mullen AM, Hamill RM.

Proteome Sci. 2013 Mar 20;11(1):9. doi: 10.1186/1477-5956-11-9.

Supplemental Content

Loading ...
Support Center